696 terminated. 696 Phase 2, 144 Phase 1, 68 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 696 | Terminated 696 |
| Phase 1 | 144 | Terminated 144 |
| Phase 3 | 68 | Terminated 68 |
Follow Vascular Diseases: new trials by email Literature Review of Vascular Diseases trials Research Report on Vascular Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| YN001-004 in Patients With Coronary Atherosclerosis in Australia Dose 1 YN001, Dose 2 YN001, Evolocumab - Coronary Artery Disease, Coronary Atherosclerotic Disease | Phase 2 | Terminated | Beijing Inno Medicine Co., Ltd. | 3 | 2026-02-25 | 2026-09-23 |
| A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 PF-07868489 - Pulmonary Hypertension | Phase 2 | Terminated | Pfizer | 42 | 2025-11-10 | 2026-11-02 |
| An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM) zagociguat 15mg - Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) | Phase 2 | Terminated | Tisento Therapeutics | 37 | 2025-08-18 | 2026-11-03 |
| REGN5381 in Adult Participants With Uncontrolled Hypertension REGN5381, Placebo - Uncontrolled Hypertension | Phase 2 | Terminated | Regeneron Pharmaceuticals | 34 | 2025-04-16 | 2025-10-23 |
| ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency INZ-701 - Gene Mutations, Pseudoxanthoma Elasticum | Phase 2 | Terminated | Inozyme Pharma | 22 | 2024-06-19 | 2026-10-19 |
| A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma Forimtamig, Carfilzomib, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 21 | 2023-12-08 | 2026-09-29 |
| IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack BI 765845, Placebo matching BI 765845 - Myocardial Infarction | Phase 2 | Terminated | Boehringer Ingelheim | 160 | 2023-12-05 | 2026-07-27 |
| A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema AVD-104 - Diabetic Macular Edema, Diabetic Retinopathy | Phase 2 | Terminated | Aviceda Therapeutics, Inc. | 21 | 2023-11-30 | 2025-07-14 |
| Maimonides Minocycline in Stroke Study Minocycline - Stroke, Acute, Ischemic Stroke | Phase 2 / Phase 3 | Terminated | Maimonides Medical Center | 2 | 2023-11-01 | 2025-12-17 |
| Treatment of Elevated Blood Pressures in Early Pregnancy Nifedipine, Labetalol - Elevated Blood Pressure, Pregnancy Induced Hypertension | Phase 2 | Terminated | Marshall University | 2 | 2023-07-11 | 2024-11-21 |
| PR3-AAV Resilient Remission or PRRR Obinutuzumab, Rituximab - Granulomatosis With Polyangiitis, Microscopic Polyangiitis | Phase 2 | Terminated | Mayo Clinic | 6 | 2023-06-30 | 2026-05-06 |
| Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone Pioglitazone 15mg - Intracerebral Haemorrhage, Intraventricular | Phase 2 | Terminated | University of Maryland, Baltimore | 1 | 2023-05-08 | 2026-04-28 |
| Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants LTP001 - Pulmonary Arterial Hypertension | Phase 2 | Terminated | Novartis Pharmaceuticals | 31 | 2023-03-27 | 2026-01-27 |
| Immunonutrition for Diabetic Foot Ulcers Lovaza, L-Arginine Powder, Vitamin C - Diabetes Mellitus, Diabetic Peripheral Neuropathy | Phase 2 / Phase 3 | Terminated | Prisma Health-Midlands | 1 | 2023-02-08 | 2024-12-27 |
| Epinephrine in the Pediatric Intensive Care Unit: A Dose-Effect Trial Epinephrine 0.5 mcg/kg, Epinephrine 1 mcg/kg - Hypotension | Phase 2 | Terminated | Boston Children's Hospital | 15 | 2023-02-08 | 2026-07-07 |
| A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Modakafusp Alfa, Daratumumab - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Teva Branded Pharmaceutical Products R&D LLC | 15 | 2023-01-23 | 2026-01-30 |
| Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine - Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation | Phase 2 | Terminated | Kite, A Gilead Company | 19 | 2022-11-01 | 2026-03-10 |
| Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH Riociguat Oral Tablet, Placebo - Pulmonary Vascular Disorder, Primary Pulmonary Hypertension | Phase 2 | Terminated | Heidelberg University | 35 | 2022-10-24 | 2026-01-21 |
| Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Ichnos Sciences SA | 29 | 2022-09-27 | 2025-01-17 |
| Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2, ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2, Placebo - Wound Heal, Wound Healing Disturbance of | Phase 2 | Terminated | Ilya Pharma | 1 | 2022-09-26 | 2025-03-05 |
Showing 20 of 696. Sign in to see all of them.
Multiple Myeloma (247) · Stroke (60) · Hypertension (46) · Hypertension, Pulmonary (43) · Neoplasms, Plasma Cell (42) · Lymphoma (41) · Waldenstrom Macroglobulinemia (40) · Leukemia, Lymphocytic, Chronic, B-Cell (38) · Recurrence (38) · Lymphoma, Non-Hodgkin (37) · Myelodysplastic Syndromes (36) · Hodgkin Disease (33) · Ischemic Stroke (33) · Leukemia (33) · Lymphoma, Mantle-Cell (30)
Cardiovascular Diseases (677) · Hemic and Lymphatic Diseases (309) · Immune System Diseases (303) · Hematologic Diseases (295) · Hemorrhagic Disorders (291) · Neoplasms by Histologic Type (285) · Hemostatic Disorders (284) · Immunoproliferative Disorders (282) · Blood Protein Disorders (280) · Lymphoproliferative Disorders (280) · Paraproteinemias (277) · Neoplasms (273) · Neoplasms, Plasma Cell (237) · Pathological Conditions, Signs and Symptoms (224)
Dexamethasone (72) · Bortezomib (46) · Cyclophosphamide (34) · Calcium Dobesilate (31) · Lenalidomide (30) · Rituximab (24) · Melphalan (23) · pomalidomide (19) · fludarabine phosphate (18) · Filgrastim (17) · Tacrolimus (17) · carfilzomib (16) · Antilymphocyte Serum (13) · Saline Solution (13) · daratumumab (13)
National Cancer Institute (NCI) (18) · Novartis Pharmaceuticals (16) · Masonic Cancer Center, University of Minnesota (10) · Pfizer (10) · Gilead Sciences (9) · M.D. Anderson Cancer Center (9) · Mayo Clinic (9) · NYU Langone Health (8) · Bayer (6) · Incyte Corporation (6) · Massachusetts General Hospital (6) · University of Arkansas (6) · Weill Medical College of Cornell University (6) · Dana-Farber Cancer Institute (5) · Fred Hutchinson Cancer Center (5)
United States (494) · Germany (69) · Canada (66) · United Kingdom (60) · France (52) · Spain (43) · Italy (38) · Australia (28) · Netherlands (25) · Belgium (22) · Poland (20) · Denmark (19) · South Korea (18) · Switzerland (18) · Czechia (17)
James R Berenson, MD (4) · Amitabha Mazumder, MD (3) · Maurizio Zangari, MD (3) · Ravi Vij, M.D. (3) · Alfred Chung, MD (2)
PMID 31527168, PMID 35244208, PMID 15014939, PMID 15016484, PMID 15030519, PMID 15791633, PMID 15885816, PMID 16673051, PMID 16990385, PMID 17276373, PMID 17470830, PMID 17579184, PMID 18032779, PMID 18434652, PMID 18752857, PMID 18949772, PMID 19118065, PMID 19179301, PMID 19190233, PMID 19293413, PMID 19833379, PMID 19958867, PMID 20067838, PMID 20185783, PMID 20634684, PMID 21062996, PMID 21146637, PMID 21325353, PMID 21386089, PMID 21403127, PMID 21423999, PMID 21527519, PMID 21593252, PMID 21596735, PMID 21700934, PMID 21784661, PMID 21873264, PMID 21874061, PMID 21900080, PMID 22080968, PMID 22105611, PMID 22340437, PMID 22430088, PMID 22496216, PMID 22520250, PMID 22719060, PMID 22936827, PMID 22983573, PMID 23074206, PMID 23205612
2018 (8), 2017 (6), P30CA015704 (5), 2016 (4), 2019 (4), 2008 (3), 2023 (3), P30CA015083 (3), P30CA016058 (3), U10CA021115 (3), 2009 (2), 2015 (2), P30CA022453 (2), P50NS044148 (2), U10CA032102 (2)